NCT04973098Unknown1 期
An Open-Label, Dose Escalation/Dose Exploration, Phase I Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single/Multiple Infusion of CT0181 Injection in Patients With Advanced Hepatocellular Carcinoma
Peking University1 个研究点 分布在 1 个国家目标入组 13 人开始时间: 2021年8月5日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 发起方
- 入组人数
- 13
- 试验地点
- 1
- 主要终点
- 1.Dose-Limiting Toxicity（DLT）
研究概览
简要总结
A Phase I Clinical Study of CT0181 cells in Patients with Advanced Hepatocellular Carcinoma
详细描述
Primary objectives:
Evaluate the safety and tolerance of CT0181 cells in patients with advanced hepatocellular carcinoma within 28 days after the first infusion
Secondary objectives:
Evaluate the metabolic kinetics of CT0181 cells ; Evaluate overall safety and tolerability ; Evaluate the initial efficacy of CT0181 cell infusion in the treatment of advanced hepatocellular carcinoma with positive Glypican-3（GPC3 ）expression.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Aged 18 to 75 years, either sex；
- •Patients with clinically or pathologically confirmed hepatocellular carcinoma were treated with surgery or local treatment It is not suitable for surgery or local radical treatment;
- •Progression or intolerance after at least one previous systemic treatment, or due to specific reasons unable to receive systemic treatment.
- •According to Barcelona Clinic Liver Cancer（BCLC）, the patients are classified into Grade C or Grade B unsuitable for local treatment/progressive disease after local treatment;
- •In tumor tissue samples GPC3 is detected positive by immunohistochemistry (IHC);
- •According to Response Evaluation Criteria in SolidTumors（RECIST1.1）,patients have at least one evaluable target lesion;
- •Expected survival is > 12 weeks;
- •Cirrhosis status Child-Pugh score: ≤7
- •Eastern Cooperative Oncology Group Performance Status score: 0 to 1 point;
- •If the patient is HBsAg positive or HBcAb positive, DNA of the hepatitis B virus should be <2000 IU/ml. HBsAg positive patients must receive antiviral treatment ;
- •Acceptable routine blood test showing no contraindication to the lymphodepletion pretreatment and adequate liver, renal, cardiovascular, respiratory function;
- •Have venous accesses for apheresis;
- •Subjects of childbearing age must undergo a serum pregnancy test . In addition, they should be willing to use a reliable method of contraception during the trial (within 52 weeks after cell infusion); male subjects whose spouses are women of childbearing age should undergo sterilization surgery or agree to use a reliable method of contraception during the trial; Understand and sign informed consent.
排除标准
- •Pregnant or breast-feeding women;
- •Hepatitis virus C antibodies ,Human Immunodeficiency Virus（HIV） antibodies or Syphilis Serological tests are positive;
- •Any uncontrol active infection, including but not limited to active tuberculosis;
- •Have clinically significant thyroid dysfunction except the stable control after treatment;
- •Previous or present hepatic encephalopathy;
- •Current clinically significant ascites;
- •Imaging results:≥50% of the liver is replaced by tumor or portal vein main tumor thrombus, or metastases to the central nervous system, or tumor thrombus invasion of mesenteric vein / inferior vena cava;
- •Subjects have known active autoimmune diseases
- •The side effects caused by the previous treatment of the subjects did not return to Common Terminology Criteria for Adverse Events（CTCAE） ≤1; except hair loss and other tolerable events determined by investigator;
- •Patients who had received systemic steroids or other immunosuppressive agents within 7 days before apheresis, except inhaled steroids;
- •History of severe allergy ;
- •Has signs of central nervous system disease or an abnormal neurological examination with clinical significance;
- •Subjects with unstable or active ulcers, gastrointestinal bleeding, or pump inhibitor intolerance;
- •Patients with a history of organ transplantation or waiting for organ transplantation;
- •Previously received Programmed cell Death-1/Programmed cell Death-Ligand 1 monoclonal antibody therapy within 4 weeks or local treatment and systemic chemiotherapy within 2 weeks or immunotheray and molecular targeted drugs within 1 week before apheresis;
- •Previously received GPC3 targeted therapy;
- •Major surgery or significant trauma occurred within 4 weeks before apheresis, or it is expected that major surgery needs to be performed during the trial;
- •Patients who had incurable malignant tumors in the past 5 years or at the same time, except cervical cancer in situ and basal cell carcinoma of skin;
- •Other serious diseases that may restrict the subjects from participating in the trial ；
- •The researcher assessed that the subjects were unable or unwilling to comply with the requirements of the trial protocol.
结局指标
主要结局
1.Dose-Limiting Toxicity（DLT）
时间窗: 28days
Safety
Maximal Tolerable Dose（MTD）
时间窗: 28days
tolerability evaluation
Treatment Emergent Adverse Event（TEAE）
时间窗: 28days
Incidence rate
Adverse Event of Special Interest
时间窗: 28 days
Incidence rate
次要结局
未报告次要终点
研究者
Shen Lin
Professor
Peking University
研究点 (1)
Loading locations...
相似试验
进行中（未招募）
1 期
Phase I Clinical Trial of CT0180 Cells in the Treatment of Hepatocellular CarcinomaAdvanced Hepatocellular CarcinomaNCT04756648Zhejiang University21
招募中
1 期
Study of AU409 Capsule in Advanced Hepatocellular Carcinoma Patients Who Failed Standard TreatmentAdvanced Hepatocellular CarcinomaNCT06374485Lee's Pharmaceutical Limited18
尚未招募
2 期
HLX07 Combination Therapy or Motherapy in Patient With Advanced Hepatocellular CarcinomaAdvanced Hepatocellular CarcinomaNCT05290220Shanghai Henlius Biotech60
终止
1 期
A Phase 1a/1b Study of ACTM-838 in Patients With Advanced Solid TumorsSolid TumorNCT06336148Actym Therapeutics, Inc.10
进行中（未招募）
1 期
A Phase I/II Study to Evaluate AZD5851 in GPC3+ Advanced/Recurrent Hepatocellular CarcinomaHepatocellular CarcinomaNCT06084884AstraZeneca94